36 Phase 1 clinical data for single-dose subcutaneous injection of RLYB116, a C5 blocking Affibody® molecule linked to an Albumod® albumin binding domain

Authors
Category Primary study
JournalImmunobiology
Year 2023
This article has no abstract
Epistemonikos ID: 8479b28c4933d50da1ecb61ae0a84b5738402bf1
First added on: Dec 07, 2023